Within this framework, the projects underway are acting on three fronts
Many users report success at 250mcg for mild to moderate injuries
Medical contraindications and usewithcaution groups Even if regulators dont ban it outright, clinicians and safetyreview papers suggest avoiding or proceeding with extreme caution if you have: Active pancreatitis or high risk of pancreatitis Preclinical work links some GLP1like pathways (relevant to BPC157 formulations) with pancreatitis risk
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
Translation to human research is not established
Not a Primary Treatment for Bacterial Overgrowth or Excessive Sebum Production: GHK-Cu does not directly target P
